Gu et al reported the mutation combined with revised international prognostic scoring system (MIPSS-R) to evaluate a patient with myelodysplasia. The authors are from Southeast University in Nanjing, China.
Patient selection: myelodysplasia
Parameters:
(1) mutation risk score
(2) IPSS-R of Greenberg et al, from 0 to 10
Status
Risk Category
Points
no mutation
low
0
only SF3B1
low
0
one mutation other than SF3B1
intermediate-1
1
2 to 4 mutations
intermediate-2
2
5 or more mutations
high
3
MIPSS-R =
= (1.047 * (mutation risk score)) + (0.641 * (IPSS-R))
Interpretation:
• The MIPSS-R ranges from 1.28 to 8.59
MIPSS-R
Risk Category
Median Overall Survival
1.28 to 2.24
very low
> 60 months
2.33 to 3.93
low
> 60 months
4.02 to 4.34
intermediate
44.4 months
4.57 to 5.30
high
11.7 months
5.62 to 8.59
very high
5.9 months
Performance:
• The area under the ROC curve is 0.79 in the training cohort but 0.62 in the validation cohort.
Continue Reading
